Structure–activity relationships of some complex I inhibitors  by Miyoshi, Hideto
 .Biochimica et Biophysica Acta 1364 1998 236–244
Structure–activity relationships of some complex I inhibitors
Hideto Miyoshi )
Di˝ision of Applied Life Sciences, Graduate School of Agriculture, Kyoto Uni˝ersity, Sakyo-ku, Kyoto 606-01, Japan
Received 17 October 1997; revised 30 December 1997; accepted 5 January 1998
Abstract
A wide variety of complex I inhibitors act at or close to the ubiquinone reduction site. Identification of the structural
factors required for exhibiting inhibitory actions on the basis of structure–activity relationships is useful to elucidate the
manner in which inhibitors interact with the enzyme. This review summarizes studies on the structure–activity relationship
of rotenoids, piericidins, capsaicins, pyridinium-type inhibitors and modern synthetic agrochemicals acting at mitochondrial
complex I. q 1998 Elsevier Science B.V.
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1. Introduction
There are a wide variety of complex I inhibitors
acting at or close to the ubiquinone reduction site
w x1,2 . Structure–activity studies of complex I in-
hibitors are important not only to elucidate the struc-
tural factors required for their inhibitory action, but
also to determine the structural properties of the
ubiquinone reduction site in the enzyme. In addition,
detailed comparisons of inhibitory actions of struc-
turally different inhibitors will provide clues to the
mechanism of redox-driven proton pumping of the
enzyme. In general, to identify important structural
factors from the study of structure–activity relation-
ships, a series of derivatives in which the chemical
structures have been systematically modified are
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needed. Without sufficient structural variation, impor-
tant structural factors and their complementary ef-
fects may be overlooked. In this respect, however,
the number of complex I inhibitors for which detailed
structure–activity studies have been conducted using
a wide variety of derivatives is small. In this article,
structure–activity studies of rotenoids, piericidins,
capsaicins and pyridinium-type inhibitors will be re-
viewed. Although similar studies on other types of
complex I inhibitors have been published, these four
series of inhibitors were chosen because of their
historical importance to research on complex I and
usefulness as probes for exploring complex I func-
tion. The detailed mechanisms of action of these
inhibitors will not be discussed since this was re-
w xviewed in the article by Degli Esposti 2 . Further-
more, since novel types of complex I inhibitors are
believed to hold important positions in most modern
w xsynthetic insecticides and acaricides 3 , the chemical
features of agrochemicals which have been recently
marketed in many countries will also be reviewed.
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2. Structure–activity studies of rotenoids
Natural rotenone is the most widely used inhibitor
of complex I because of its high inhibitory potency
and commercial availability. Rotenone consists of a
 .five-ring structure A- to E-rings and has three chiral
Fig. 1. Structures of natural rotenone, 5Xa-epirotenone, 5Xb-epi-
rotenone and synthetic rotenones. For synthetic rotenones, Xs
w xalkyls or alkoxys 10 . The three dimensional structure of rotenone
w xobtained by X-ray crystallographic analysis 7 is shown at the
bottom.
 X .centers 6a-C, 12a-C and 5 -C, Fig. 1 . The stereo-
chemistry of rotenone has been assigned as 6aS,
X w x12aS, 5 R configuration 4 . All known natural
rotenoids have been isolated in the thermodynami-
w xcally stable cis-BrC ring fusion 5,6 . The three-di-
mensional structure of rotenone determined by X-ray
w xcrystallographic analysis 7 is also shown in Fig. 1
 .the bottom . Rotenone is bent at the face of contact
between the B- and C-rings.
 XUsing synthetic rotenone stereoisomers 5a-epi-
X .rotenone and 5b-epirotenone, Fig. 1 , it has been
shown that the inhibitory potency of 5Xb-epirotenone,
in which B- and C-ring planes are almost coplanar, is
about 100-fold less active than natural rotenone with
w xmammalian mitochondrial complex I 8,9 , indicating
that the bent form is essential for the activity. This
conclusion is supported by the observation that the
inhibitory potency of rotenol, in which the whole
molecular conformation is not fixed due to opening
of the C-ring is about 200-fold less active than
w x w xnatural rotenone 8,10 . Levett et al. 11 have also
shown an important role for the BrC ring system by
synthesizing rotenone-related inhibitors which lack
the core BrC ring. The inhibitory potency as well as
the manner of inhibition of 5Xa-epirotenone differ
considerably from those of natural rotenone irrespec-
w xtive of slight differences in the E-ring moiety 9 .
That is, the potency of this isomer is about 10-fold
less than that of rotenone and the inhibition pattern
varies from non-competitive to competitive as the
concentration of exogenous quinone increases. This
indicates that the configuration of the isopropenyl
group attached to the E-ring is also important for the
activity. These observations obtained with rotenone
stereoisomers demonstrate that the whole molecular
 .structure or shape of rotenone is strictly recognized
by mammalian complex I.
A similar structure–activity relationship of
rotenone stereoisomers has been reported for the
proton-pumping NADH-Q oxidoreductase in potato
 . w xtuber Solanum tuberosum L. mitochondria 9 . In
contrast, with respect to the proton-pumping NADH-
Q oxidoreductase of Escherichia coli, the sensitivity
of the enzyme to rotenone and its stereoisomers is
markedly decreased and the differences in the in-
hibitory potencies of the three inhibitors are ambigu-
w xous 9 . This suggests that only part of the rotenone
molecule is recognized by this enzyme. It is notewor-
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thy that the sensitivity of non-proton-pumping
NADH-Q oxidoreductase in potato tuber mitochon-
dria and E. coli to inhibition by rotenone stereoiso-
mers is much lower than that of the proton-pumping
w xenzyme 9 , as is also the case for natural rotenone
w x12,13 . This is consistent with the notion that the
proton-pumping machinery is close to the ubiquinone
w xreduction site 14–16 .
Besides the stereochemical properties of rotenone,
w xUeno et al. 10 investigated the effects of the sub-
stituents in the A-ring on the activity using synthetic
rotenoids in which the E-ring moiety of rotenone was
 .substituted by a benzyloxy group Fig. 1 . The native
 .chemical structure 2,3-dimethoxy substitution is the
most favorable for the activity with bovine heart
mitochondrial complex I. This may be because a
specific spatial organization of the hydrogen-bond
acceptable methoxy oxygens is required for tight
fitting into the binding site. It is, however, notewor-
thy that derivatives possessing other substitution pat-
terns such as 1,3-dimethoxy and 2,3-dimethyl groups
do not necessarily lose all activity. Replacing one of
the two methoxy groups with an ethoxy group results
in almost complete retention of activity, indicating
that the binding environment of the A-ring moiety is
sufficiently spacious to accommodate substituents
larger than the methoxy group. The sensitivity of
proton-pumping NADH-Q oxidoreductase of potato
tuber and E. coli to inhibition by the rotenone ana-
logues is much lower than that of the bovine enzyme.
The 2,3-dimethoxy substituted analogue showed the
best activity with the potato enzyme, although the
extent of the differences in potency among the
derivatives possessing various substitution patterns is
rather small, being within one order of magnitude.
For the E. coli enzyme, however, the 2,3-dimethoxy
substituted derivative did not show the best activity;
for instance, 2-monomethoxy and 3-monomethoxy
derivatives were several times more potent than the
2,3-dimethoxy derivative. These findings indicated
that the local binding environment of the A-ring
moiety of rotenone in bovine complex I is specific
and differs considerably from those in potato and E.
coli enzymes.
w xFurthermore, Ueno et al. 10 showed that the
apparent inhibitory potency of the derivative lacking
the 12-C5O group in the C-ring is completely re-
tained with bovine complex I, whereas the manner of
inhibition of this inhibitor differs somewhat from that
of natural rotenone. This derivative is approximately
7- and 3-fold more potent than natural rotenone for
potato and E. coli enzymes, respectively. These find-
ings indicate that the 12-C5O group is not essential
for exhibiting apparent inhibitory action.
3. Structure–activity studies of piericidins
Many kinds of Streptomyces strains produce pieri-
cidin homologues. Piericidin A has been used as a
very potent inhibitor of complex I from various bio-
logical sources. The structure of piericidin A origi-
w xnally proposed by Takahashi et al. 17 in 1965 was
w xrevised later by the same group in 1977 18 , as
shown in Fig. 2. It should be appreciated that an
incorrect structure of piericidin A has been often
cited even in recent literature.
Detailed structure–activity studies on piericidin
analogues including both natural and synthetic prod-
w xucts have been performed by Takahashi et al. 17
w xand Yoshida et al. 18–21 with mammalian and
insect mitochondria. The natural side chain structure
of piericidin A is not essential for the activity since
piericidin B, C and D analogues, in which the side
chain structure in the region from C-5 to C-13 differs
from that of piericidin A, exhibit activity as high as
w xor only slightly less than that of piericidin A 21 ; for
instance, the relative potencies of piericidins A, B, C
and D are 1.0, 0.84, 1.1, and 0.80, respectively.
Based on structure–activity studies of a number of
synthetic piericidin analogues possessing different
side chains, it was concluded that a branched methyl
group at C-3 and unsaturation between C-2 and C-3
w xare important for potent activity 21 . Actually, this
structural unit is completely conserved for another
Fig. 2. Structure of piericidin A.
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w xclass of potent synthetic inhibitors, ubicidines 22 .
However, as derivatives possessing a simple long
w xalkyl chain retain fairly potent activity 23 , the side
chain might serve primarily to enhance the hydropho-
bicity of the whole molecule. In evidence of this, the
location of the hydrophobic side chain at either the 1X-
or 2X-position of the pyridine ring does not affect the
w xinhibitory potency 21,23 .
A free pyridinol hydroxy group in the pyridine
ring moiety, which resembles the quinone ring of
w xubiquinone, is essential for activity 24,25 . To eluci-
date the functional contributions of the other sub-
 X Xstituents on the pyridine ring namely, 2 -Me, 4 -MeO
X . w xand 5 -MeO groups , Yoshida et al. 20,21 synthe-
sized a variety of piericidin analogues in which sub-
stitution patterns on the pyridine ring as well as side
chain structure were modified simultaneously. Their
assay results were, however, confusing. For instance,
lack of the 2X-Me group results in marked loss of
inhibitory potency, whereas loss of both the 2X-Me
and 5X-MeO groups restores the inhibitory potency
irrespective of the side chain structure.
4. Structure–activity studies of capsaicins
 .Capsaicin Fig. 3 , the pungent principle of red
pepper species, acts as a competitive inhibitor for
ubiquinone with bovine heart mitochondrial complex
Fig. 3. Structures of natural capsaicin and potent synthetic cap-
saicins. For synthetic capsaicins, Xsalkyls or alkoxys; YsH or
w xMe 31 .
w xI 26 . Using submitochondrial particles prepared from
bovine heart mitochondria and several bacterial mem-
w xbranes, Yagi 27 demonstrated that the inhibition of
NADH-Q oxidoreductase activities of several organ-
isms by capsaicin correlated well with the presence
of an energy coupling site in this segment of the
respiratory chain. That is, the sensitivity to capsaicin
inhibition of NADH-Q oxidoreductase that bears an
 .energy coupling site NDH-1 is much higher than
 .that of the enzyme lacking such a site NDH-2 . Yagi
w x27 consequently concluded that capsaicin inhibition
correlates better with the presence of a coupling site
than inhibition by rotenone, piericidin A or DCCD
 X .N, N -dicyclohexylcarbodiimide , which had been
thought to discriminate fairly well between NDH-1
w xand NDH-2 14 . Thus, capsaicin is a useful reagent
for investigating the mechanism of energy coupling
associated with complex I.
The structural requirements of capsaicin analogues
for other pharmacological effects such as analgesic
activity have been examined closely e.g., Refs.
w x.28,29 , whereas structure–activity studies regarding
electron-transfer inhibition are limited. Chudapongse
w xand Janthasoot 30 found that methyl capsaicin is
several times more potent than natural capsaicin with
mammal mitochondrial complex I, indicating that the
phenolic OH group is not essential for the activity.
w xOn the other hand, Shimomura et al. 26 have shown
that capsaicin analogues with an acyl group of 10 to
12 carbons are much more potent than natural cap-
saicin, indicating that the hydrophobicity of the acyl
moiety favors activity. Based on these studies, Satoh
w xet al. 31 performed a detailed structure–activity
study using a variety of synthetic capsaicins which
were prepared by modifying each region of the three
 .sections A to C, Fig. 3 of the prototype capsaicin,
as follows.
Modification both of the substitution pattern and of
the number of methoxy groups on the benzene ring,
which may be superimposable on the quinone ring of
ubiquinone due to a structural similarity, did not
markedly affect the inhibitory potency with bovine
heart mitochondrial complex I. Concerning the dipo-
lar amide bond unit which can serve as a hydrogen-
bond donor and acceptor, alteration of the position of
this functional group in the molecule and chemical
modifications of this unit such as N-methylation do
not affect the inhibitory potency. Regarding the moi-
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ety corresponding to the alkyl side chain, a rigid
 .diphenylether structure Fig. 3 is more inhibitory
than a flexible alkyl chain. Thus, the rule regarding
the variation of the inhibitory potency depending
upon structural modification is rather ambiguous. This
may be not only because that the high rotational
freedom of A- and B-sections of capsaicin make
these moieties fit flexibly into the binding pocket in a
dissimilar way, but also that capsaicins interact at
w xproposed multiple sites in complex I 27,31 .
w xSatoh et al. 31 also examined the inhibition by
the synthetic capsaicins of NDH-1 and NDH-2 activi-
ties in potato tuber mitochondria and E. coli plasma
membranes. The sensitivity to inhibition by various
synthetic capsaicins differs markedly between NDH-1
and NDH-2, supporting the notion that the sensitivity
against capsaicin inhibition correlates well with the
presence of an energy coupling site in the enzyme
w x27 . It is noteworthy that several potent synthetic
capsaicins discriminated between NDH-1 and NDH-2
w xmuch better than natural capsaicin 31 .
5. Structure–activity studies of N-methylphenyl-
pyridiniums
 q.N-Methyl-4-phenylpyridinium MPP and its
 .alkyl derivatives Fig. 4 have recently attracted our
 q.Fig. 4. Structures of N-methyl-4-phenylpyridiniums MPPs ,
 w N-methylquinoliniums and MP6 N-methyl-4- 2- p-tert-butyl-
. x . w xbenzyl propyl pyridinium . Xsalkyls or alkoxys 33,41 .
attention not only because their neurotoxicity is
w xthought to be related to Parkinsonian syndrome 32 ,
but also because mode of action studies of these
inhibitors have suggested that they are bound at two
distinct sites on bovine heart mitochondrial complex I
w x 1 q33,34 . As MPP binds to the so-called ‘rotenone-
w xsite’ 37,38 , this proposal would mean that there are
also two distinct ubiquinone binding sites in complex
I. This might be very helpful in elucidating the
terminal electron transfer step in the enzyme. Thus,
mode of action as well as structure–activity studies
of MPPq analogues should provide clues as to the
mechanism of energy-coupled electron transfer in the
enzyme.
q  .The inhibitory potency of MPP itself mM order
is much poorer than that of classical potent inhibitors
 .nM order such as piericidin A and rotenone for
mammalian mitochondrial complex I. The develop-
ment of inhibition of this hydrophillic inhibitor is a
w xvery slow process which continues for hours 33 . For
q  .simple alkyl analogues of MPP Fig. 4 , the in-
hibitory potency increases and the inhibition is at-
tained in a shorter time with increases in hydropho-
w xbicity of the alkyl substituent 33 . Besides the effect
of the hydrophobicity, structure–activity profiles of
the pyridinium-type inhibitors are complicated, and
consequently important structural features for the in-
hibition are still ambiguous.
It is not clear whether a positive charge on the
pyridinium ring is functionally essential for the activ-
 .ity since the neutral i.e., pyridine form is more
potent than the pyridinium form for relatively weak
w xinhibitors 33,39,40 , although an important role for a
positive charge has been claimed for relatively potent
w xpyridiniums 33,41 . The methyl group attached to a
pyridine nitrogen atom might not be essential because
an ethyl or even a bulky benzyl derivative retains the
w xactivity 34,41 . For substituents on the pyridinium
ring, the substitution position as well as its steric
shape are not restricted for eliciting potent inhibition
1 Although two sites of interaction have been suggested for
14 w xrotenone and piericidin A using C-labeled inhibitors 35,36 ,
these earlier studies were challenged by the recent radioligand
w3 x w xassay using H dihydrorotenone 37 , wherein the signal-to-noise
ratio was markedly improved due to high specific activity of the
ligand.
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w x34,40,41 . Furthermore, the N-methylpyridinium ring
itself is not essential for the activity since other
aromatic rings such as bulky N-methylquinolinium
 . w xFig. 4 can functionally substitute for it 41 .
Thus, the physicochemical structural factors, ex-
cept for hydrophobicity, of the pyridinium-type in-
hibitors required for inhibition have yet to be defined.
It is, however, likely that only two factors, a positive
 .charge i.e., electrophilic property , which may inter-
 .act with the proposed anionic residue s in the bind-
w xing site 33 , and marked hydrophobicity, which facil-
itates the passage of the cationic inhibitor to the
binding site through the hydrophobic environment in
the membrane, are required for potent inhibition.
The effects of the hydrophobic anion tetraphenyl-
 y. qboron TPB on the inhibitory action of MPP
analogues is noteworthy. The presence of TPBy po-
tentiates the inhibition of less hydrophobic MPPq
analogues and facilitates the development of inhibi-
w xtion 33 , although the potentiation effects have been
confirmed even for hydrophobic MPPq analogues
w x y41 . These effects of TPB can be accounted for
first by an increase in MPPq concentration in the
membrane lipid phase due to ion pair formation and
second by facilitating MPPq passage through the
hydrophobic barrier to the binding site. Interestingly,
when TPBy present in molar excess over MPPq
analogues, the former partially reverses the inhibition
by the latter. This complicated effect of TPBy along
with pH dependence of MPPq inhibition prompted
w x qGluck et al. 33 to conclude that MPP analogues
are bound at two sites, one accessible to relatively
 .hydrophillic inhibitors termed the ‘hydrophillic site’
and one shielded by a hydrophobic barrier on the
 .enzyme the ‘hydrophobic site’ , and that occupation
of both sites is required for complete inhibition.
Using novel potent pyridinium and quinolinium in-
w xhibitors, Miyoshi et al. 41 provided strong evidence
to support this idea, and further demonstrated that
q  .both the MPP inevitably ubiquinone binding sites
contribute to redox-driven proton pumping. In addi-
tion, they succeeded in synthesis of a fairly selective
inhibitor of the hydrophillic site, MP6 N-methyl-4-
w  . x .2- p-tert-butylbenzyl propyl pyridinium, Fig. 4 .
The availability of this inhibitor and further modified
derivatives will stimulate interesting additional stud-
ies aimed at resolving the mechanism of the terminal
electron transfer step in complex I.
6. Structural feature of complex I inhibitors as
pesticides
Pesticides must be safe, both to humans and to
non-target organisms, and leave no harmful residues,
either in the crops or in the environment. In this
respect, respiratory inhibitors have been thought diffi-
cult to develop as pesticides since a highly selective
toxicity between target and non-target organisms can-
not be obtained due to similarities in electron-transfer
 .Fig. 5. Structures of Fenpyroximate Nihon Noyaku , Pyridaben
 .  .Nissan Chemical Industries , Tebufenpyrad Mitsubishi Kagaku ,
 .  .Fenazaquin Dow Elanco and SAN 548A Sandoz .
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w xmachinery in the respiration chain 42 . However, a
number of chemical companies have recently an-
nounced new excellent respiratory inhibitors which
satisfy the above demands. These respiratory in-
hibitors are expected to hold important positions in
w xmost modern synthetic insecticides and acaricides 3 .
Among these, compounds whose target site is mito-
chondrial complex I will be briefly reviewed.
Novel structural types of insecticidesracaricides
are listed in Fig. 5. The properties of these com-
pounds as insecticidesracaricides have been re-
w xviewed 43,44 . These compounds inhibit mitochon-
drial complex I activity by disturbing the terminal
electron-transfer step between Fe–S cluster N-2 and
 w x.Q the so called ‘rotenone site’ 1,45–47 . Since
these compounds are potent inhibitors of both mam-
malian and insect mitochondrial complex I, their low
toxicity to mammals should be due to specific
metabolic decomposition rather than target insensitiv-
ity, as investigated closely with Fenpyroximate
w x48,49 . Although structure–activity studies of these
compounds as pesticide have been reported at inter-
national conferences on pesticide chemistry, no stud-
ies of in vitro activity have been published. Since in
vitro activity is not necessarily correlated to in vivo
activity, definition and comparison of the structural
factors required for the inhibition of complex I are
impractical at present.
It is, however, likely that they have broad struc-
tural features in common, notably heterocyclic com-
pounds containing two nitrogen atoms and hydropho-
bic tail structure. The lone-pair containing group of
the heterocyclic moiety might play an important role
in binding to the enzyme through specific interactions
with some residues. However, it seems to be mean-
ingless to superimpose their heterocyclic ring moi-
eties in any particular way since the steric hindrance
surrounding the nitrogen atoms and electron density
on the atoms differ markedly. The manner of binding
of the heterocyclic ring might vary depending upon
both the bulkiness of the substituents on the ring and
the tail structure. On the other hand, the primary role
of the tail moiety in the inhibition should be enhance-
ment of hydrophobicity of the whole molecule. The
high degree of hydrophobicity of the inhibitor might
be energetically favorable to partitioning into and
passage through the hydrophobic environment of the
ubiquinone catalytic site which is believed to be part
of the membrane-embedded segment of complex I
w x14–16 . This feature of the functional division of the
inhibitor molecule is important for other inhibitors
such as piericidins and capsaicins, as described above.
On the basis of COMPASS COMmon geometrical
.PAttern Search System and ‘molecular field fitting’
w xanalyses, Akagi et al. 50 suggested that the active
conformations of the agrochemicals are non-planar;
that is, the heterocyclic ring and the tail moieties are
perpendicular to each other. It is interesting to note
that a non-planar structure is also important for
w xrotenoids and capsaicins 9,31 . Although bulky tert-
 .butyl or tert-butylphenyl groups are common struc-
tural factors of the novel agrochemicals, it is unclear
whether this structural unit is based on some biora-
tional design.
7. Conclusions
Through structure–activity studies of the above
complex I inhibitors, particularly on mammalian mi-
tochondria, we conclude that the important structural
factors which drastically affect the inhibitory potency
 .by several orders of magnitude are not necessarily
obvious for each inhibitor. For instance, only the
pyridinol hydroxy group is undoubtedly essential for
the action of piericidin. Other functional groups on
the pyridinol ring are indeed important to maintain
high potency, but do not determine the exhibition of
inhibitory effects. The bent form of the rotenone
molecule is a very important structural factor, whereas
the two methoxy groups in the A-ring, 12-C5O
group in the C-ring and presence of the E-ring itself
are not essential for exhibiting apparent inhibition.
Particularly for capsaicins and pyridinium-type in-
hibitors, it is not easy to define the structural proper-
ties important for inhibition, except hydrophobicity of
the molecule. These findings along with the observa-
tion that a wide variety of structurally different in-
hibitors act at the ubiquinone catalytic site in com-
w xmon 1,2 suggest that this site in mammalian mito-
chondrial complex I is spacious enough to accommo-
date various inhibitors in a dissimilar manner depend-
ing upon structural specificity. The manner of bind-
ing of complex I inhibitors might not follow the
so-called ‘key and keyhole’ relation in which multi-
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ple functional groups of the inhibitors are thought to
interact tightly with their binding environment in a
similar manner. It should also be mentioned that the
complexity of the explanation of the inhibitory mech-
anism as well as the structure–activity relationship of
complex I inhibitors would be due to the presence of
more than one ubiquinone reduction site in the en-
w xzyme 2,33,41,51 . The number of ubiquinone reduc-
tion sites, and the spatial and functional relationship
of the sites must be elucidated to fully understand the
mechanism of inhibition of complex I inhibitors.
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